JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy

The prognosis of AML is generally poor, with 5-year survival rate of 25%. There has been substantial progress in identification of new therapeutic targets, along with approval of at least three targeted therapies for AML in recent years. Nevertheless, treatment has largely remained unchanged over co...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Biol Ther
Main Authors: Babu, Govind, Chaudhuri, Padmaparna, Rajappa, Manoj, Biswas, Manjusha, Sansar, Bipinesh, Rajegowda, Chethan, Radhakrishnan, Aneesha, Advani, Jayshree, Tewary, Biplab, Radhakrishnan, Padhma, Thiyagarajan, Saravanan, Chatterjee, Aditi, Upadhayaya, Ram Shankar, Majumder, Pradip K
Format: Artigo
Language:Inglês
Published: Taylor & Francis 2020
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7834080/
https://ncbi.nlm.nih.gov/pubmed/33356802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2020.1831371
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items